Rachel Jimenez, MD, Chair of Quality and Safety in the Department of Radiation Oncology at Massachusetts General Hospital, and Associate Professor of Radiation Oncology at Harvard Medical School, recently discussed the unmet needs in radiation treatment for patients with breast cancer.
Speaking at the 41st Annual Miami Breast Cancer Conference, Jimenez emphasized the importance of personalized treatment in radiation oncology. Traditionally, a standardized dose regimen has been applied to patients with breast cancer, but there is a growing recognition that treatment can be customized to better suit individual patients. This tailored approach involves delivering appropriate doses to specific areas for each patient.
While efforts are underway to identify which patients truly require radiation and determine the optimal dosage for each case, several clinical trials are currently utilizing established genomic signatures to assist in decision-making. These signatures, commonly used in systemic therapy decisions, are being explored to determine if certain patients can safely forgo radiation treatment.
In addition to genomic signatures, emerging radio signatures are being developed to evaluate the efficacy of radiation therapy. Although these signatures are still in the early stages of development and not yet ready for widespread adoption, there is considerable interest in their potential impact on improving treatment outcomes.
Despite these advancements, there are still unmet needs in radiation treatment for breast cancer patients. Further validation through clinical trials is necessary to accurately determine which patients would benefit most from specific radiation doses and techniques. Jimenez concluded by stressing the importance of ongoing research to address these remaining challenges in the field.
